[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 721
Citations 0
News From the Food and Drug Administration
November 3, 2015

New Atypical Antipsychotic

JAMA. 2015;314(17):1789. doi:10.1001/jama.2015.14005

The atypical antipsychotic cariprazine, marketed as Vraylar, has gained FDA approval for treating schizophrenia and bipolar disorder in adults.

“It is important to have a variety of treatment options available to patients with mental illnesses so that treatment plans can be tailored to meet a patient’s individual needs,” Mitchell Mathis, MD, director of the division of psychiatry products in the FDA’s Center for Drug Evaluation and Research, said in a statement (http://1.usa.gov/1LjZEgw).

First Page Preview View Large
First page PDF preview
First page PDF preview